Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) today announced that it has acquired the MastaScope� and OvaScope� technology and products from Solos Endoscopy. The Company had previously sold these technologies to Solos in February 2007 with the intention of Solos developing the market and revenues for the products. However, Solos� resources have been focused on marketing and sales of their core endoscopic products.

The MastaScope� has been developed and designed to assist in detection of breast cancer. The Company will now evaluate the competition and market for this product, as well as its potential of being a complementary product to Lifeline�s First Warning early breast cancer detection system.

The OvaScope� has been developed and designed to assist in the early detection of ovarian cancer. The preliminary testing that has been conducted on the OvaScope� to date has been very promising. This data and the market are currently being reviewed and the results of this review will determine the direction the Company will take regarding the OvaScope�.

Jim Holmes, CEO of Lifeline Biotechnologies, stated, �While we were hopeful that our sale of these products to Solos was to be the beginning of a very beneficial synergistic relationship, we are excited to have MastaScope� and OvaScope� back in our growing portfolio of medical products. We will continue to push these products forward, along with our First Warning early breast cancer detection product. It is our belief that a diversified portfolio of products will position us to not only capitalize on various areas in the medical field, but to give Lifeline numerous opportunities to build shareholder value for our stockholders.�

Lifeline Biotechnologies has in the past year filed for a patent on the recent technological advancements of the First Warning System�, which has achieved the robust capability of identifying and classifying abnormalities of the breast with sensitivities of 95% to 100% and specificities of 87% to 90%. Currently, it is a well known fact that mammograms are missing an estimated 30 to 40% of the breast cancers.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing, successful development of the Company�s product and regulatory and shareholder approval for anticipated actions.

Lifeline Biotech (CE) (USOTC:LLBO)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Lifeline Biotech (CE) Charts.
Lifeline Biotech (CE) (USOTC:LLBO)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Lifeline Biotech (CE) Charts.